Improvement of the OraQuick Ebola Rapid Antigen Test
Agency: | |
---|---|
State: | Pennsylvania |
Level of Government: | Federal |
Category: |
|
Opps ID: | NBD00159553952724049 |
Posted Date: | Sep 19, 2023 |
Due Date: | |
Source: | Members Only |
- Contract Award Date: Sep 27, 2022
- Contract Award Number: 75A50122C00079
- Task/Delivery Order Number:
- Modification Number:
- Contractor Awarded Unique Entity ID:
- Contract Opportunity Type: Justification (Updated)
- All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
- Updated Published Date: Sep 19, 2023 10:20 am EDT
- Original Published Date: Sep 30, 2022 10:18 am EDT
- Inactive Policy: 30 days after published date
- Updated Inactive Date: Oct 19, 2023
- Original Inactive Date:
- Authority: FAR 6.302-1 - Only one responsible source (except brand name)
-
Initiative:
- None
- Product Service Code: AN13 - Health R&D Services; Health care services; Experimental Development
-
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
-
Place of Performance:
Bethlehem , PAUSA
This requirement is to improve the OraQuick® Ebola Rapid Antigent Test. The OraQuick® Ebola Rapid Antigen Test 510(k) was cleared by FDA in October 2019. As of June 2022, there is limited supply of critical reagents (both control and diagnostic antibodies) used in the Ebola 510(k) cleared device. The Government seeks to make the Ebola 510(k) cleared device independent of the aforementioned critical reagents, improve manufacturing capabilities, sensitivity and shelf in order to better respond to public health emergencies. Therefore, the project scope will be expanded beyond preliminary device performance testing, with a goal to improve the quality of the test performance and stability.
The attached J&A amendment approved on 9/14/2023 increases the J&A ceiling and revises the Statement of Work to include the completion of analytical and clinical validation studies and regulatory activities for 510(k) clearance of the second-generation OraQuick® Ebola Rapid Antigen Test. The modification was determined to be in-scope.
- O’NEILL HOUSE OFFICE BUILDING
- WASHINGTON , DC 20515
- USA
- Davis Perkins
- davis.perkins@hhs.gov
- Connie Petitjean
- constance.petitjean@hhs.gov
- Phone Number 2026971900
- Sep 19, 2023 10:20 am EDTJustification (Updated)
- Sep 19, 2023 10:13 am EDT Justification (Updated)
- Sep 19, 2023 09:58 am EDT Justification (Updated)
- Oct 30, 2022 11:56 pm EDT Justification (Original)
- Jul 30, 2022 11:55 pm EDT Special Notice (Original)
TRY FOR FREE
Not a USAOPPS Member Yet?
Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.